Spectral Medical Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Chris Seto

Chief executive officer

CA$901.4k

Total compensation

CEO salary percentage	50.6%
CEO tenure	3.1yrs
CEO ownership	0.2%
Management average tenure	no data
Board average tenure	2.9yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Chris Seto's remuneration changed compared to Spectral Medical's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	n/a	n/a	-CA$16m
Sep 30 2023	n/a	n/a	-CA$10m
Jun 30 2023	n/a	n/a	-CA$9m
Mar 31 2023	n/a	n/a	-CA$7m
Dec 31 2022	CA$901k	CA$457k	-CA$8m
Sep 30 2022	n/a	n/a	-CA$7m
Jun 30 2022	n/a	n/a	-CA$7m
Mar 31 2022	n/a	n/a	-CA$7m
Dec 31 2021	CA$883k	CA$419k	-CA$7m
Sep 30 2021	n/a	n/a	-CA$8m
Jun 30 2021	n/a	n/a	-CA$8m
Mar 31 2021	n/a	n/a	-CA$7m
Dec 31 2020	CA$590k	CA$338k	-CA$9m
Sep 30 2020	n/a	n/a	-CA$8m
Jun 30 2020	n/a	n/a	-CA$8m
Mar 31 2020	n/a	n/a	-CA$7m
Dec 31 2019	CA$391k	CA$139k	-CA$5m

Compensation vs Market: Chris's total compensation ($USD655.14K) is above average for companies of similar size in the Canadian market ($USD174.31K).

Compensation vs Earnings: Chris's compensation has increased whilst the company is unprofitable.

CEO

Chris Seto

3.1yrs

Tenure

CA$901,387

Compensation

Mr. Christopher Seto, also known as Chris, serves as Director for Spectral Medical Inc. since November 12, 2021. He has been Chief Executive Officer of Spectral Medical Inc. since April 1, 2021. Mr. Seto h...

Board Members

Name	Position	Tenure	Compensation	Ownership
Christopher Seto	CEO & Director	2.5yrs	CA$901.39k	0.21% CA$ 281.9k
Paul Walker	Director	23.1yrs	CA$103.58k	0.67% CA$ 883.1k
Janelle D'Alvise	Independent Director	2.9yrs	CA$120.42k	no data
David Feigal	Director	less than a year	no data	no data
Anthony Bihl	Independent Director	less than a year	CA$156.15k	0.56% CA$ 733.7k
William Stevens	Independent Director	9.7yrs	CA$118.00k	0.28% CA$ 362.7k
Jun Hayakawa	Independent Director	6yrs	no data	no data

2.9yrs

Average Tenure

70yo

Average Age

Experienced Board: EDT's board of directors are not considered experienced ( 2.9 years average tenure), which suggests a new board.

Spectral Medical Management

Management criteria checks 0/4

Key information

Recent management updates

Less than half of directors are independent

Spectral Medical Inc. Announces Board Changes

Spectral Medical Inc., Annual General Meeting, Jun 07, 2024

Spectral Medical Inc. Announces Executive Changes

Spectral Medical Inc. Announces Executive Changes

Spectral Medical Inc. Appoints David W. Feigal to Its Board of Directors

Recent updates

Spectral Medical Provides Tigris Trial Update

Less than half of directors are independent

Price target increased by 13% to CA$1.80

Spectral Medical Inc. Announces Board Changes

Full year 2023 earnings: EPS and revenues miss analyst expectations

Spectral Medical Inc., Annual General Meeting, Jun 07, 2024

New minor risk - Market cap size

Spectral Medical Inc. Provides Update on the Company's Tigris Trial

Spectral Medical Announces Major Milestone by Reaching Its Interim Enrollment Target of 90 Patients

Spectral Medical Inc. Provides Early February Tigris Trial Update

Spectral Medical Provides January Tigris Trial Update

Spectral Medical Inc. l Enrolls Patient 82 in Its Phase 3 FDA Tigris Septic Shock Trial

Spectral Medical Inc. Provides November Tigris Trial Update

Spectral Medical Inc. Announces Executive Changes

Spectral Medical Inc. Announces Executive Changes

Spectral Medical Inc. Announces Publication of Tigris Trial Methods Paper

Third quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

Spectral Medical Provides Tigris Trial Update

New minor risk - Shareholder dilution

Spectral Medical Inc. announced that it has received CAD 6.217075 million in funding

Spectral Medical Inc. announced that it expects to receive CAD 5 million in funding from Paradigm Capital Inc.

Second quarter 2023 earnings released: CA$0.014 loss per share (vs CA$0.011 loss in 2Q 2022)

Spectral Medical Inc. Announces Tigris Clinical Trial Update

Spectral Medical Inc. Appoints David W. Feigal to Its Board of Directors

Spectral Medical Inc. Provides Update on Continued Favorable Tigris Clinical Trial Enrollment

Spectral Medical Inc. Provides Update on Favorable Tigris Clinical Trial Enrollment

Consensus revenue estimates increase by 186%

Consensus revenue estimates decrease by 61%, EPS upgraded

First quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

Spectral Medical Inc. Announces Resignation of Jim Funk as Director

No longer forecast to breakeven

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Spectral Medical Inc. Provides Update on Tigris Clinical Trial

Consensus forecasts updated

Consensus forecasts updated

Price target decreased to CA$2.10

Forecast to breakeven in 2024

Spectral Medical Inc. announced that it has received CAD 6.8364 million in funding

Spectral Medical Inc. announced that it expects to receive CAD 8.5 million in funding

Spectral Medical Inc. announced that it expects to receive CAD 8.5 million in funding

Consensus forecasts updated

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Spectral Medical Provides Update on Tigris Clinical Trial

US FDA Grants Spectral Medical Breakthrough Device Designation for Toraymyxin™ for the Treatment of Endotoxemic Septic Shock

Spectral Medical Inc. Elects James Funk as Director

Spectral Medical Inc. Appoints Sam Amory as Dialco, President

First quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Price target decreased to CA$2.10

Forecast breakeven date pushed back to 2024

Consensus revenue estimates fall by 44%

Spectral Medical Inc., Annual General Meeting, Jun 09, 2022

Spectral Medical Inc. Through Its Wholly-Owned Subsidiary Dialco Medical Inc. Provides Clinical Trial Update on Tigris, A Follow on Study Designed to Build on Knowledge Gained from the Earlier Euphrates Trial

We're Keeping An Eye On Spectral Medical's (TSE:EDT) Cash Burn Rate

Forecast to breakeven in 2023

Third quarter 2021 earnings released: CA$0.008 loss per share (vs CA$0.007 loss in 3Q 2020)

Price target decreased to CA$2.85

Independent Chairman of the Board recently bought CA$180k worth of stock

Independent Director Kevin Giese has left the company

Forecast breakeven moved forward to 2022

First quarter 2021 earnings released: CA$0.007 loss per share (vs CA$0.015 loss in 1Q 2020)

Consensus forecasts updated

Full year 2020 earnings released: CA$0.039 loss per share (vs CA$0.022 loss in FY 2019)

Spectral Medical Inc.'s (TSE:EDT) Path To Profitability

Spectral Medical Inc., Annual General Meeting, Jun 03, 2021

Independent Director exercised options to buy CA$104k worth of stock.

Spectral Medical Inc. Announces Chief Executive Officer Changes, Effective April 1, 2021

Spectral Medical Inc Crescendo Communications to Provide Investor Relations Services in the United States

Spectral Medical Announces That Its Wholly-Owned Subsidiary Dialco Medical Has Been Granted FDA IDE Authorization to Conduct Trial of Dimi for Home Hemodialysis Use

Spectral Medical (TSE:EDT) Is In A Good Position To Deliver On Growth Plans